Rare Cancers: Challenges and Roadmap for R&D Innovations

Drug development for Rare cancers is challenging because it is difficult to obtain relevant data from very few patients. The oncology community is increasingly facing a disproportionate fraction of the total burden of cancers, hence, requiring multi-stakeholder cooperation and collaboration to complete rare cancer trials.

Nevertheless, new insights into the biology of rare cancers have led to an explosion in knowledge and the development of targeted agents. In addition, drug development strategies and the availability of new agents for rare cancers are at risk of stalling owing to the ever-increasing complexity and costs of clinical trials. Finding solutions . . .